APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bacille Calmette-Guerin Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Bacille Calmette-Guerin Vaccine Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchBacille Calmette-Guerin Vaccine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Bacille Calmette-Guerin Vaccine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Bacille Calmette-Guerin Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bacille Calmette-Guerin Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Bacille Calmette-Guerin Vaccine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Bacille Calmette-Guerin Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Bacille Calmette-Guerin Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Bacille Calmette-Guerin Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bacille Calmette-Guerin Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Bacille Calmette-Guerin Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Bacille Calmette-Guerin Vaccine market include China National Biotec, Merck, Taj Pharmaceuticals, Serum Institute of India, Queen Saovabha Mem. Inst, Microgen, Japan BCG Lab, IVAC – Institute of Vaccines and Medical Biologicals and GreenSignal Bio Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Bacille Calmette-Guerin Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Bacille Calmette-Guerin Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Bacille Calmette-Guerin Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bacille Calmette-Guerin Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Bacille Calmette-Guerin Vaccine Segment by Company

China National Biotec

Merck

Taj Pharmaceuticals

Serum Institute of India

Queen Saovabha Mem. Inst

Microgen

Japan BCG Lab

IVAC – Institute of Vaccines and Medical Biologicals

GreenSignal Bio Pharma

Biomed Lublin

BioFarma

Ataulpho de Paiva

AJ Vaccines

Bacille Calmette-Guerin Vaccine Segment by Type

Immune Vaccine

Therapy Vaccine

Bacille Calmette-Guerin Vaccine Segment by Application

Self-Procurement

UNICEF

Other

Bacille Calmette-Guerin Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Bacille Calmette-Guerin Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Bacille Calmette-Guerin Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Bacille Calmette-Guerin Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Bacille Calmette-Guerin Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bacille Calmette-Guerin Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bacille Calmette-Guerin Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bacille Calmette-Guerin Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bacille Calmette-Guerin Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Bacille Calmette-Guerin Vaccine industry.

Chapter 3: Detailed analysis of Bacille Calmette-Guerin Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Bacille Calmette-Guerin Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Bacille Calmette-Guerin Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Bacille Calmette-Guerin Vaccine Industry Trends Table 2. Bacille Calmette-Guerin Vaccine Industry Drivers Table 3. Bacille Calmette-Guerin Vaccine Industry Opportunities and Challenges Table 4. Bacille Calmette-Guerin Vaccine Industry Restraints Table 5. Global Bacille Calmette-Guerin Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Bacille Calmette-Guerin Vaccine Revenue Share by Company (2021-2026) Table 7. Global Bacille Calmette-Guerin Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Bacille Calmette-Guerin Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Bacille Calmette-Guerin Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Bacille Calmette-Guerin Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Bacille Calmette-Guerin Vaccine Company, Product Type & Application Table 13. Global Bacille Calmette-Guerin Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Bacille Calmette-Guerin Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immune Vaccine Table 18. Significant Companies of Therapy Vaccine Table 19. Global Bacille Calmette-Guerin Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Bacille Calmette-Guerin Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Bacille Calmette-Guerin Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Bacille Calmette-Guerin Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Bacille Calmette-Guerin Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Bacille Calmette-Guerin Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Self-Procurement Table 30. Significant Companies of UNICEF Table 31. Significant Companies of Other Table 32. Global Bacille Calmette-Guerin Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Bacille Calmette-Guerin Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Bacille Calmette-Guerin Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Bacille Calmette-Guerin Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Bacille Calmette-Guerin Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Bacille Calmette-Guerin Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Bacille Calmette-Guerin Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Bacille Calmette-Guerin Vaccine Sales by Region (2021-2026) & (K Units) Table 44. Global Bacille Calmette-Guerin Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Bacille Calmette-Guerin Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Bacille Calmette-Guerin Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Bacille Calmette-Guerin Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Bacille Calmette-Guerin Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Bacille Calmette-Guerin Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Bacille Calmette-Guerin Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Bacille Calmette-Guerin Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Bacille Calmette-Guerin Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Bacille Calmette-Guerin Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Bacille Calmette-Guerin Vaccine Sales by Country (2021-2026) & (K Units) Table 57. Global Bacille Calmette-Guerin Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Bacille Calmette-Guerin Vaccine Sales by Country (2027-2032) & (K Units) Table 59. Global Bacille Calmette-Guerin Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Bacille Calmette-Guerin Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Bacille Calmette-Guerin Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Bacille Calmette-Guerin Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Bacille Calmette-Guerin Vaccine Sales Value Market Share by Country (2027-2032) Table 64. China National Biotec Company Information Table 65. China National Biotec Business Overview Table 66. China National Biotec Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. China National Biotec Bacille Calmette-Guerin Vaccine Product Portfolio Table 68. China National Biotec Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Merck Bacille Calmette-Guerin Vaccine Product Portfolio Table 73. Merck Recent Development Table 74. Taj Pharmaceuticals Company Information Table 75. Taj Pharmaceuticals Business Overview Table 76. Taj Pharmaceuticals Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Taj Pharmaceuticals Bacille Calmette-Guerin Vaccine Product Portfolio Table 78. Taj Pharmaceuticals Recent Development Table 79. Serum Institute of India Company Information Table 80. Serum Institute of India Business Overview Table 81. Serum Institute of India Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Serum Institute of India Bacille Calmette-Guerin Vaccine Product Portfolio Table 83. Serum Institute of India Recent Development Table 84. Queen Saovabha Mem. Inst Company Information Table 85. Queen Saovabha Mem. Inst Business Overview Table 86. Queen Saovabha Mem. Inst Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Queen Saovabha Mem. Inst Bacille Calmette-Guerin Vaccine Product Portfolio Table 88. Queen Saovabha Mem. Inst Recent Development Table 89. Microgen Company Information Table 90. Microgen Business Overview Table 91. Microgen Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Microgen Bacille Calmette-Guerin Vaccine Product Portfolio Table 93. Microgen Recent Development Table 94. Japan BCG Lab Company Information Table 95. Japan BCG Lab Business Overview Table 96. Japan BCG Lab Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Japan BCG Lab Bacille Calmette-Guerin Vaccine Product Portfolio Table 98. Japan BCG Lab Recent Development Table 99. IVAC – Institute of Vaccines and Medical Biologicals Company Information Table 100. IVAC – Institute of Vaccines and Medical Biologicals Business Overview Table 101. IVAC – Institute of Vaccines and Medical Biologicals Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. IVAC – Institute of Vaccines and Medical Biologicals Bacille Calmette-Guerin Vaccine Product Portfolio Table 103. IVAC – Institute of Vaccines and Medical Biologicals Recent Development Table 104. GreenSignal Bio Pharma Company Information Table 105. GreenSignal Bio Pharma Business Overview Table 106. GreenSignal Bio Pharma Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. GreenSignal Bio Pharma Bacille Calmette-Guerin Vaccine Product Portfolio Table 108. GreenSignal Bio Pharma Recent Development Table 109. Biomed Lublin Company Information Table 110. Biomed Lublin Business Overview Table 111. Biomed Lublin Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Biomed Lublin Bacille Calmette-Guerin Vaccine Product Portfolio Table 113. Biomed Lublin Recent Development Table 114. BioFarma Company Information Table 115. BioFarma Business Overview Table 116. BioFarma Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. BioFarma Bacille Calmette-Guerin Vaccine Product Portfolio Table 118. BioFarma Recent Development Table 119. Ataulpho de Paiva Company Information Table 120. Ataulpho de Paiva Business Overview Table 121. Ataulpho de Paiva Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Ataulpho de Paiva Bacille Calmette-Guerin Vaccine Product Portfolio Table 123. Ataulpho de Paiva Recent Development Table 124. AJ Vaccines Company Information Table 125. AJ Vaccines Business Overview Table 126. AJ Vaccines Bacille Calmette-Guerin Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. AJ Vaccines Bacille Calmette-Guerin Vaccine Product Portfolio Table 128. AJ Vaccines Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Bacille Calmette-Guerin Vaccine Distributors List Table 132. Bacille Calmette-Guerin Vaccine Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Bacille Calmette-Guerin Vaccine Product Image Figure 2. Global Bacille Calmette-Guerin Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bacille Calmette-Guerin Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Bacille Calmette-Guerin Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Bacille Calmette-Guerin Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Bacille Calmette-Guerin Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immune Vaccine Image Figure 10. Therapy Vaccine Image Figure 11. Global Bacille Calmette-Guerin Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Bacille Calmette-Guerin Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Bacille Calmette-Guerin Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Bacille Calmette-Guerin Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Type (2021-2032) Figure 17. Self-Procurement Image Figure 18. UNICEF Image Figure 19. Other Image Figure 20. Global Bacille Calmette-Guerin Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Bacille Calmette-Guerin Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Bacille Calmette-Guerin Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Bacille Calmette-Guerin Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Bacille Calmette-Guerin Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Bacille Calmette-Guerin Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Bacille Calmette-Guerin Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Bacille Calmette-Guerin Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Bacille Calmette-Guerin Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Bacille Calmette-Guerin Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Bacille Calmette-Guerin Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Bacille Calmette-Guerin Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Bacille Calmette-Guerin Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Bacille Calmette-Guerin Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Bacille Calmette-Guerin Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Bacille Calmette-Guerin Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Bacille Calmette-Guerin Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Bacille Calmette-Guerin Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Bacille Calmette-Guerin Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Bacille Calmette-Guerin Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Vaccine
  • Therapy Vaccine
Applications
  • Self-Procurement
  • UNICEF
  • Other
Companies covered
  • China National Biotec
  • Merck
  • Taj Pharmaceuticals
  • Serum Institute of India
  • Queen Saovabha Mem. Inst
  • Microgen
  • Japan BCG Lab
  • IVAC – Institute of Vaccines and Medical Biologicals
  • GreenSignal Bio Pharma
  • Biomed Lublin
  • BioFarma
  • Ataulpho de Paiva
  • AJ Vaccines

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Bacille Calmette-Guerin Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Bacille Calmette-Guerin Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Bacille Calmette-Guerin Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Bacille Calmette-Guerin Vaccine Market Dynamics
  1. 2.1 Bacille Calmette-Guerin Vaccine Industry Trends
  2. 2.2 Bacille Calmette-Guerin Vaccine Industry Drivers
  3. 2.3 Bacille Calmette-Guerin Vaccine Industry Opportunities and Challenges
  4. 2.4 Bacille Calmette-Guerin Vaccine Industry Restraints
3 Bacille Calmette-Guerin Vaccine Market by Company
  1. 3.1 Global Bacille Calmette-Guerin Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Bacille Calmette-Guerin Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Bacille Calmette-Guerin Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Bacille Calmette-Guerin Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Bacille Calmette-Guerin Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Bacille Calmette-Guerin Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Bacille Calmette-Guerin Vaccine Company Product Type and Application
  8. 3.8 Global Bacille Calmette-Guerin Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Bacille Calmette-Guerin Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Bacille Calmette-Guerin Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Bacille Calmette-Guerin Vaccine Market by Type
  1. 4.1 Bacille Calmette-Guerin Vaccine Type Introduction
  2. 4.1.1 Immune Vaccine
  3. 4.1.2 Therapy Vaccine
  4. 4.2 Global Bacille Calmette-Guerin Vaccine Sales Volume by Type
  5. 4.2.1 Global Bacille Calmette-Guerin Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Bacille Calmette-Guerin Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Bacille Calmette-Guerin Vaccine Sales Value by Type
  9. 4.3.1 Global Bacille Calmette-Guerin Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Bacille Calmette-Guerin Vaccine Sales Value Share by Type (2021-2032)
5 Bacille Calmette-Guerin Vaccine Market by Application
  1. 5.1 Bacille Calmette-Guerin Vaccine Application Introduction
  2. 5.1.1 Self-Procurement
  3. 5.1.2 UNICEF
  4. 5.1.3 Other
  5. 5.2 Global Bacille Calmette-Guerin Vaccine Sales Volume by Application
  6. 5.2.1 Global Bacille Calmette-Guerin Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Bacille Calmette-Guerin Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Bacille Calmette-Guerin Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Bacille Calmette-Guerin Vaccine Sales Value by Application
  10. 5.3.1 Global Bacille Calmette-Guerin Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Bacille Calmette-Guerin Vaccine Sales Value Share by Application (2021-2032)
6 Bacille Calmette-Guerin Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Bacille Calmette-Guerin Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Bacille Calmette-Guerin Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Bacille Calmette-Guerin Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Bacille Calmette-Guerin Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Bacille Calmette-Guerin Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Bacille Calmette-Guerin Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Bacille Calmette-Guerin Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Bacille Calmette-Guerin Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Bacille Calmette-Guerin Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Bacille Calmette-Guerin Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Bacille Calmette-Guerin Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Bacille Calmette-Guerin Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Bacille Calmette-Guerin Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Bacille Calmette-Guerin Vaccine Sales Value Share by Country, 2025 VS 2032
7 Bacille Calmette-Guerin Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Bacille Calmette-Guerin Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Bacille Calmette-Guerin Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Bacille Calmette-Guerin Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Bacille Calmette-Guerin Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Bacille Calmette-Guerin Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Bacille Calmette-Guerin Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Bacille Calmette-Guerin Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Bacille Calmette-Guerin Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Bacille Calmette-Guerin Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Bacille Calmette-Guerin Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China National Biotec
  2. 8.1.1 China National Biotec Company Information
  3. 8.1.2 China National Biotec Business Overview
  4. 8.1.3 China National Biotec Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 China National Biotec Bacille Calmette-Guerin Vaccine Product Portfolio
  6. 8.1.5 China National Biotec Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Bacille Calmette-Guerin Vaccine Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Taj Pharmaceuticals
  14. 8.3.1 Taj Pharmaceuticals Company Information
  15. 8.3.2 Taj Pharmaceuticals Business Overview
  16. 8.3.3 Taj Pharmaceuticals Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Taj Pharmaceuticals Bacille Calmette-Guerin Vaccine Product Portfolio
  18. 8.3.5 Taj Pharmaceuticals Recent Developments
  19. 8.4 Serum Institute of India
  20. 8.4.1 Serum Institute of India Company Information
  21. 8.4.2 Serum Institute of India Business Overview
  22. 8.4.3 Serum Institute of India Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Serum Institute of India Bacille Calmette-Guerin Vaccine Product Portfolio
  24. 8.4.5 Serum Institute of India Recent Developments
  25. 8.5 Queen Saovabha Mem. Inst
  26. 8.5.1 Queen Saovabha Mem. Inst Company Information
  27. 8.5.2 Queen Saovabha Mem. Inst Business Overview
  28. 8.5.3 Queen Saovabha Mem. Inst Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Queen Saovabha Mem. Inst Bacille Calmette-Guerin Vaccine Product Portfolio
  30. 8.5.5 Queen Saovabha Mem. Inst Recent Developments
  31. 8.6 Microgen
  32. 8.6.1 Microgen Company Information
  33. 8.6.2 Microgen Business Overview
  34. 8.6.3 Microgen Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Microgen Bacille Calmette-Guerin Vaccine Product Portfolio
  36. 8.6.5 Microgen Recent Developments
  37. 8.7 Japan BCG Lab
  38. 8.7.1 Japan BCG Lab Company Information
  39. 8.7.2 Japan BCG Lab Business Overview
  40. 8.7.3 Japan BCG Lab Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Japan BCG Lab Bacille Calmette-Guerin Vaccine Product Portfolio
  42. 8.7.5 Japan BCG Lab Recent Developments
  43. 8.8 IVAC – Institute of Vaccines and Medical Biologicals
  44. 8.8.1 IVAC – Institute of Vaccines and Medical Biologicals Company Information
  45. 8.8.2 IVAC – Institute of Vaccines and Medical Biologicals Business Overview
  46. 8.8.3 IVAC – Institute of Vaccines and Medical Biologicals Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 IVAC – Institute of Vaccines and Medical Biologicals Bacille Calmette-Guerin Vaccine Product Portfolio
  48. 8.8.5 IVAC – Institute of Vaccines and Medical Biologicals Recent Developments
  49. 8.9 GreenSignal Bio Pharma
  50. 8.9.1 GreenSignal Bio Pharma Company Information
  51. 8.9.2 GreenSignal Bio Pharma Business Overview
  52. 8.9.3 GreenSignal Bio Pharma Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GreenSignal Bio Pharma Bacille Calmette-Guerin Vaccine Product Portfolio
  54. 8.9.5 GreenSignal Bio Pharma Recent Developments
  55. 8.10 Biomed Lublin
  56. 8.10.1 Biomed Lublin Company Information
  57. 8.10.2 Biomed Lublin Business Overview
  58. 8.10.3 Biomed Lublin Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biomed Lublin Bacille Calmette-Guerin Vaccine Product Portfolio
  60. 8.10.5 Biomed Lublin Recent Developments
  61. 8.11 BioFarma
  62. 8.11.1 BioFarma Company Information
  63. 8.11.2 BioFarma Business Overview
  64. 8.11.3 BioFarma Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 BioFarma Bacille Calmette-Guerin Vaccine Product Portfolio
  66. 8.11.5 BioFarma Recent Developments
  67. 8.12 Ataulpho de Paiva
  68. 8.12.1 Ataulpho de Paiva Company Information
  69. 8.12.2 Ataulpho de Paiva Business Overview
  70. 8.12.3 Ataulpho de Paiva Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Ataulpho de Paiva Bacille Calmette-Guerin Vaccine Product Portfolio
  72. 8.12.5 Ataulpho de Paiva Recent Developments
  73. 8.13 AJ Vaccines
  74. 8.13.1 AJ Vaccines Company Information
  75. 8.13.2 AJ Vaccines Business Overview
  76. 8.13.3 AJ Vaccines Bacille Calmette-Guerin Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AJ Vaccines Bacille Calmette-Guerin Vaccine Product Portfolio
  78. 8.13.5 AJ Vaccines Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Bacille Calmette-Guerin Vaccine Value Chain Analysis
  2. 9.1.1 Bacille Calmette-Guerin Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Bacille Calmette-Guerin Vaccine Sales Mode & Process
  6. 9.2 Bacille Calmette-Guerin Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Bacille Calmette-Guerin Vaccine Distributors
  9. 9.2.3 Bacille Calmette-Guerin Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst